Clinical Access
Clinically Accessed Therapy
This therapy is available exclusively to ROEHN Members and requires asynchronous clinical verification through our licensed telehealth network.
Format
Injectable / Sublingual
Frequency
See instructions
Overview
A dual-pathway metabolic therapy engineered to recalibrate appetite signaling, optimize insulin function, and elevate cellular energy. Semaglutide activates GLP-1 receptors to slow gastric emptying, stabilize blood glucose, and reduce appetite with precision—while methylcobalamin (B12) enhances mitochondrial output, mood, and metabolic efficiency. This formulation is designed for individuals seeking sustainable weight optimization, reduced cravings, and elevated vitality without the extremes of traditional dieting. Pure, pharmaceutical-grade, and compounded under the highest sterility and potency standards.
Mechanism of Action
GLP-1 Receptor Activation: Semaglutide mimics endogenous GLP-1, a hormone central to appetite control and glucose regulation. • Slows gastric emptying • Improves insulin response • Decreases glucagon release • Enhances satiety signaling Cellular Energy Amplification (B12): Methylcobalamin supports: • Optimal mitochondrial ATP production • Neurological function • Metabolic clarity and endurance Together, these pathways promote a smoother metabolic rhythm, reduced caloric intake, and improved physiological resilience.
Key Benefits
Suggested Use
Administered as a weekly micro-dose according to your clinician’s protocol. Results compound progressively, with most individuals experiencing appetite changes within 1–2 weeks and body-composition shifts across 4–12 weeks.
